With an eye on patients™
we are committed to developing solutions to help people facing serious eye disorders. At EyePoint Pharmaceuticals, you can see our dedication in action.
President & Chief Executive Officer & Board Director
President, CEO and Board Director Nancy Lurker leads our mission to improve the lives of people facing serious eye disorders. With over 30 years in the pharmaceutical industry driving scientific and commercial innovation across public and private companies, she has a proven track record of maximizing the potential of new therapies and implementing US and global drug launches in diverse therapy areas.
Jay Duker, MD
Chief Operating Officer
Chief Operating Officer, Jay S. Duker, M.D. is a leading retinal disease expert with more than 30 years in the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical, research, business, start-ups, and academic settings.
George O. Elston
Chief Financial Officer
Mr Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly traded and privately held organizations.
Chief Legal Officer & Company Secretar
Mr Honig brings more than 25 years of legal experience in the medical device, biotechnology, contract manufacturing, and legal services industries to his role at EyePoint, which he has held since November 2018.
Chief Commercial Officer
With a background in developing commercial and growth strategy, Mr Jones brings significant experience commercializing drugs and devices globally.
Chief People Officer & SVP, IT
Ms Leonard has over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management, and culture development experience.
Dario Paggiarino, MD
Senior Vice President & Chief Medical Officer
Dr Paggiarino joined EyePoint from Lpath, where he served as Senior Vice President and Chief Development Officer. Dr Paggiarino earned his degree in medicine and general surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.
Said Saim, PhD
Chief Technology Officer
Dr Saim has more than 25 years of product development experience. Dr Saim has published 22 papers in engineering and science journals, holds 18 patents, and earned a PhD in chemical engineering from the University of Kansas.
Chief Regulatory Officer
Ms. Lefebvre brings over 30 years of regulatory affairs experience in pharmaceuticals, biologics, and medical devices across all phases of development. Ms. Lefebvre has strong Ophthalmic/Ocular experience having spent nearly a decade of her career at Bausch Health where she led the successful approvals of both LOTEMAX gel and VYZULTA®.
Chief Corporate Development & Strategy Officer
Michael Pine brings strategic vision, analytics and an extensive deal sheet built over 20+ years in the pharmaceutical industry at both large and small organizations.
Göran Ando, MD
Chairman of the Board
David Guyer, MD
John Landis, PhD, MS
President & Chief Executive Officer